

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Case Count			1485	28	1052
Reaction Count	Blood and lymphatic system disorders	Anaemia	5	1	3
		Bone marrow failure	1	0	1
Pancytopenia		1	0	1	
Coagulopathy		3	1	1	
Coombs positive haemolytic anaemia		1	0	1	
Thrombocytopenia		4	1	1	
Lymphadenopathy		1	0	0	
Spleen disorder		1	0	1	
Eosinophilia		2	0	1	
Leukocytosis		4	0	1	
Neutrophilia		1	0	0	
Leukopenia		7	0	1	
Lymphopenia		3	0	1	
Agranulocytosis		3	0	1	
Neutropenia		12	0	4	
		Blood and lymphatic system disorders	49	3	18
		Cardiac disorders	Bundle branch block right	1	0
	Arrhythmia		1	0	1
	Bradycardia		3	0	2
	Extrasystoles		3	0	3
	Tachycardia		36	0	18
	Atrial fibrillation		3	0	3
	Atrial flutter		1	0	1
	Atrial tachycardia		1	0	1
	Sinus tachycardia		2	0	0
	Supraventricular tachycardia		3	0	2
	Cardiac arrest		6	3	2
	Torsade de pointes		1	0	0
	Ventricular fibrillation		2	0	2
	Ventricular tachycardia		2	0	1
	Cyanosis		1	0	1
	Palpitations		20	0	19
	Mitral valve prolapse		1	0	0
	Angina pectoris		1	0	1
	Myocardial infarction		2	0	2
	Cardiac failure		1	0	1
	Cardiomyopathy		5	1	4
	Cardiomegaly		1	0	1
	Left atrial dilatation		1	0	0
	Ventricular hypokinesia	1	0	0	
	Myocarditis	1	1	0	

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	Cardiac disorders	Cardiac disorders	100	5	65	
	Congenital, familial and genetic disorders	Heart disease congenital	3	1	2	
		Transposition of the great vessels	1	0	1	
		Trisomy 18	1	0	1	
		Trisomy 21	1	0	0	
		Cytogenetic abnormality	1	0	1	
		Hemihypertrophy	2	0	2	
		Multiple congenital abnormalities	3	0	1	
		Hernia congenital	1	0	0	
		Cleft palate	1	0	0	
		Congenital hand malformation	1	0	1	
		Limb malformation	1	0	0	
		Polydactyly	1	0	1	
		Talipes	1	0	1	
		Cerebral palsy	1	0	0	
		Kidney malformation	1	0	0	
		Pulmonary malformation	1	0	1	
			Congenital, familial and genetic disorders	21	1	12
		Ear and labyrinth disorders	Ear pain	2	0	2
			Deafness	1	0	1
	Hearing impaired		2	0	2	
	Inner ear disorder		1	0	1	
	Motion sickness		1	0	1	
	Tinnitus		15	0	13	
	Vertigo		19	0	15	
	Eustachian tube obstruction		1	0	1	
			Ear and labyrinth disorders	42	0	36
	Endocrine disorders	Inappropriate antidiuretic hormone secretion	20	0	14	
		Hypothyroidism	1	0	1	
			Endocrine disorders	21	0	15
	Eye disorders	Cataract	1	0	1	
		Xerophthalmia	1	0	1	
		Lacrimal disorder	1	0	1	
		Eye pain	5	0	4	
		Ocular discomfort	1	0	1	
		Angle closure glaucoma	1	0	1	
		Glaucoma	5	0	2	
		Conjunctivitis	1	0	0	
		Ocular hyperaemia	1	0	1	
		Blepharospasm	1	0	1	
		Oculogyric crisis	3	0	2	
		Miosis	1	0	1	

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Eye disorders	Mydriasis	26	0	18
		Eye rolling	3	0	1
		Eyelid sensory disorder	1	0	1
		Photophobia	5	0	5
		Myodesopsia	1	0	1
		Vitreous detachment	1	0	1
		Blindness	1	0	1
		Accommodation disorder	1	0	1
		Xanthopsia	1	0	1
		Diplopia	5	0	4
		Photopsia	1	0	1
		Vision blurred	14	0	11
		Visual impairment	30	0	26
		Scotoma	1	0	0
		Eye disorders	113	0	88
		Gastrointestinal disorders	Rectal tenesmus	1	0
	Dental caries		1	0	0
	Tooth disorder		1	0	0
	Tooth discolouration		1	0	1
	Gingivitis		1	0	1
	Pancreatitis		4	0	3
	Pancreatitis acute		1	0	1
	Gastric disorder		1	0	1
	Gastrointestinal disorder		1	0	1
	Rectal haemorrhage		1	0	1
	Haematemesis		4	0	1
	Melaena		1	0	0
	Colitis ulcerative		1	0	1
	Gastritis		1	0	1
	Enteritis		2	0	1
	Oesophagitis		1	0	1
	Diarrhoea		38	1	32
	Constipation	18	0	15	
Frequent bowel movements	1	0	1		
Irritable bowel syndrome	1	0	1		
Ileus paralytic	1	0	1		
Dyspepsia	12	0	10		
Abnormal faeces	2	0	2		
Flatulence	2	0	2		
Abdominal pain	14	0	12		
Abdominal pain upper	4	0	4		
Abdominal discomfort	4	0	4		

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Gastrointestinal disorders	Dysphagia	8	0	7
		Faecal incontinence	1	0	1
		Nausea	159	0	132
		Retching	2	0	2
		Vomiting	93	1	73
		Vomiting in pregnancy	1	0	1
		Intestinal obstruction	1	0	0
		Gastric ulcer	1	0	0
		Chapped lips	1	0	1
		Cheilitis	1	0	1
		Aphthous stomatitis	1	0	1
		Mouth ulceration	1	0	1
		Stomatitis	4	0	4
		Aptyalism	1	0	1
		Dry mouth	20	0	18
		Salivary hypersecretion	4	0	4
		Glossitis	4	0	1
		Tongue disorder	2	0	2
		Tongue ulceration	1	0	1
		Tongue discolouration	1	0	1
	Tongue oedema	5	0	5	
	Gastrointestinal disorders		432	2	356
	General disorders and administration site conditions	Hyperthermia	1	0	1
		Hyperthermia malignant	1	0	1
		Pyrexia	24	1	7
		Death	1	1	0
		Death neonatal	1	1	1
Sudden death		6	6	1	
Asthenia		22	0	17	
Fatigue		55	0	40	
Malaise		29	1	22	
Abasia		1	0	1	
Gait disturbance		11	0	7	
Condition aggravated		5	0	4	
Energy increased		1	0	1	
Influenza like illness		8	0	7	
Irritability		11	0	9	
Multi-organ failure		1	1	0	
Face oedema		5	0	4	
Gravitational oedema	3	0	2		
Oedema	6	0	1		
Oedema peripheral	6	0	3		

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	General disorders and administration site conditions	Chest pain	12	0	10	
		Pain	11	0	9	
		Chest discomfort	2	0	2	
		Chills	26	0	17	
		Feeling abnormal	13	0	13	
		Feeling cold	1	0	0	
		Feeling hot	3	0	2	
		Feeling jittery	4	0	3	
		Feeling of body temperature change	4	0	3	
		Hunger	1	0	1	
		Thirst	4	0	4	
		Drug interaction	9	0	0	
		Drug effect decreased	6	0	5	
		Drug ineffective	35	2	28	
		Therapeutic response decreased	2	0	1	
		Drug withdrawal syndrome	40	0	37	
		Drug withdrawal syndrome neonatal	12	0	9	
		Rebound effect	1	0	1	
			General disorders and administration site conditions	384	13	274
			Hepatobiliary disorders	Cholecystitis	1	0
		Jaundice		3	0	2
		Hepatic function abnormal		16	1	8
		Hepatic failure		5	1	2
		Hepatitis		5	1	4
		Hepatitis chronic active		1	0	1
		Hepatitis fulminant		1	0	0
		Hepatocellular injury		1	0	0
		Hepatobiliary disorders		33	3	17
		Immune system disorders	Hypersensitivity	3	0	3
			Anaphylactic shock	1	0	1
			Anaphylactoid reaction	3	0	3
			Immune system disorders	7	0	7
		Infections and infestations	Bacterial infection	1	0	0
			Cellulitis	1	0	1
			Candidiasis	1	0	0
			Genital candidiasis	1	0	1
			Gastroenteritis	1	0	1
			Infection	1	0	1
			Pneumonia	3	0	2
			Sepsis	1	1	0
			Rash pustular	1	0	0

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Infections and infestations	Nasopharyngitis	1	0	1
		Pharyngitis	3	0	3
		Sinusitis	1	0	1
		Gastritis viral	1	0	1
		Gastroenteritis viral	1	0	1
		Infections and infestations	18	1	13
	Injury, poisoning and procedural complications	Drug toxicity	1	1	1
		Poisoning	1	0	1
		Drug exposure before pregnancy	1	0	1
		Drug exposure during pregnancy	23	1	16
		Maternal drugs affecting foetus	1	1	1
		Subdural haemorrhage	1	0	1
		Fall	7	0	0
		Uterine injury	1	0	1
		Head injury	2	0	0
		Contusion	3	0	1
		Chillblains	1	0	0
		Heat stroke	2	1	1
		Inappropriate schedule of drug administration	1	0	1
		Medication error	3	0	0
		Accidental overdose	1	0	1
		Intentional overdose	7	1	6
		Overdose	10	0	5
		Post procedural haemorrhage	1	0	1
		Injury, poisoning and procedural complications	67	5	38
		Investigations	Cardiac murmur	1	0
	Electrocardiogram QT prolonged		8	1	4
	Electrocardiogram abnormal		2	0	1
	Heart rate increased		3	0	3
	Blood pressure decreased		2	0	2
	Blood pressure increased		10	0	10
	Blood prolactin increased		2	0	1
	Blood testosterone decreased		1	0	0
	Blood testosterone increased		1	0	0
Blood creatine phosphokinase increased	8		1	3	
Blood alkaline phosphatase increased	2		0	0	
Blood lactate dehydrogenase increased	1		0	0	
Bleeding time prolonged	1		0	0	
International normalised ratio decreased	1		0	0	
International normalised ratio increased	1		0	0	
Prothrombin level decreased	1		0	1	

Medicine summary - venlafaxine (to end January 2009)

Reaction Count	Investigations	Case Group	Death Outcomes	Sole
	Prothrombin level increased	2	0	0
	Red blood cell sedimentation rate increased	1	0	0
	White blood cell count increased	1	0	0
	Alanine aminotransferase increased	2	0	0
	Aspartate aminotransferase increased	1	0	0
	Blood bilirubin increased	1	0	0
	Gamma-glutamyltransferase increased	2	0	0
	Hepatic enzyme increased	1	0	0
	Liver function test abnormal	13	0	8
	Antinuclear antibody positive	2	0	0
	Blood cholesterol increased	4	0	1
	Total cholesterol/HDL ratio decreased	1	0	0
	Blood triglycerides increased	3	0	1
	Blood glucose decreased	1	0	1
	Blood glucose increased	1	0	1
	Intraocular pressure increased	1	0	1
	Body temperature decreased	1	0	1
	Weight decreased	12	0	10
	Weight increased	19	0	15
	C-reactive protein increased	1	0	0
	Semen analysis abnormal	1	0	1
	Antidepressant drug level above therapeutic	1	0	1
	Antipsychotic drug level increased	1	0	0
	Drug level above therapeutic	1	0	0
	Drug level decreased	2	0	0
	Drug level increased	3	0	0
	Blood phosphorus decreased	1	0	0
	Investigations	125	2	67
	Metabolism and nutrition disorders			
	Acidosis	2	1	0
	Decreased appetite	33	1	28
	Food craving	1	0	1
	Increased appetite	3	0	2
	Feeding disorder neonatal	1	0	1
	Weight loss poor	1	0	1
	Hypercalcaemia	1	0	0
	Hypocalcaemia	2	1	1
	Tetany	2	0	2
	Hyperchloraemia	1	1	0
	Hypochloraemia	2	0	0
	Polydipsia	1	0	1
	Hyperkalaemia	2	0	0
	Hypokalaemia	9	1	2

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Metabolism and nutrition disorders	Hypernatraemia	2	0	1
		Hyponatraemia	92	1	56
		Dehydration	6	0	4
		Fluid retention	3	0	3
		Alcohol intolerance	1	0	1
		Diabetes mellitus	1	0	1
		Gestational diabetes	1	0	1
		Hyperglycaemia	1	0	1
		Hypoglycaemia	6	0	2
		Metabolism and nutrition disorders	174	6	109
	Musculoskeletal and connective tissue disorders	Jaw disorder	1	0	1
		Systemic lupus erythematosus	1	0	1
		Arthritis	6	0	3
		Arthralgia	11	0	8
		Joint stiffness	1	0	1
		Osteoarthritis	2	0	1
		Myalgia	29	0	23
		Muscle spasms	9	0	5
		Muscle tightness	3	0	3
		Muscle twitching	19	0	13
		Hypertonia neonatal	1	0	1
		Muscle rigidity	6	0	2
		Torticollis	1	0	0
		Trismus	5	0	4
		Muscular weakness	2	0	1
		Rhabdomyolysis	4	1	1
		Mobility decreased	3	0	0
		Musculoskeletal stiffness	4	0	3
		Back pain	2	0	2
		Neck pain	1	0	1
		Pain in extremity	2	0	2
	Musculoskeletal and connective tissue disorders	113	1	76	
	Nervous system disorders	Cerebrovascular accident	4	0	4
Haemorrhagic stroke		2	0	2	
Cerebrovascular disorder		3	1	2	
Facial palsy		1	0	1	
Encephalopathy		5	0	4	
Drug withdrawal headache		1	0	1	
Headache		106	0	83	
Migraine		6	0	3	
Migraine with aura		1	0	1	

Medicine summary - venlafaxine (to end January 2009)

Reaction Count			Case Group	Death Outcomes	Sole
Reaction Count	Nervous system disorders	Benign intracranial hypertension	1	0	1
		Brain oedema	1	0	0
		Amnesia	18	0	13
		Memory impairment	5	0	2
		Cognitive disorder	2	0	2
		Disturbance in attention	15	0	11
		Mental impairment	3	0	3
		Choreoathetosis	4	0	3
		Akathisia	27	2	18
		Bradykinesia	1	0	1
		Dyskinesia	15	0	8
		Extrapyramidal disorder	7	0	4
		Hyperkinesia	5	0	3
		Hypokinesia	2	0	0
		Movement disorder	2	0	1
		Psychomotor hyperactivity	4	0	3
		Tardive dyskinesia	8	0	4
		Dystonia	19	0	11
		Opisthotonus	2	0	1
		Paresis	1	0	1
		Cogwheel rigidity	2	0	1
		Masked facies	1	0	0
		Parkinsonism	6	0	3
		Tremor	89	0	54
		Hyperreflexia	9	0	4
		Hyporeflexia	1	0	1
		Reflexes abnormal	1	0	0
		Ataxia	25	0	22
		Balance disorder	7	0	2
		Coordination abnormal	10	0	7
		Dysstasia	3	0	3
		Nystagmus	4	0	2
		Coma	5	0	2
Aphasia	1	0	0		
Consciousness fluctuating	3	0	1		
Depressed level of consciousness	5	0	1		
Lethargy	6	0	3		
Loss of consciousness	6	1	4		
Sedation	2	0	1		
Somnolence	41	0	28		
Stupor	1	0	1		
Syncope	28	0	18		

Medicine summary - venlafaxine (to end January 2009)

Reaction Count		Case Group	Death Outcomes	Sole	
	Nervous system disorders	Motor dysfunction	1	0	1
		Clonus	2	0	1
		Dizziness	117	0	95
		Head discomfort	2	0	2
		Myoclonus	3	0	0
		Neurological symptom	1	0	1
		Presyncope	2	0	2
		Tongue biting	1	0	0
		Crying	4	0	4
		Burning sensation	2	0	2
		Hyperaesthesia	5	0	4
		Paraesthesia	52	0	46
		Dysgeusia	6	0	6
		Hypoaesthesia	13	0	12
		Restless legs syndrome	1	0	1
		Sensory disturbance	5	0	4
		Dysarthria	8	0	7
		Incoherent	1	0	0
		Speech disorder	4	0	1
		Tunnel vision	1	0	1
		Visual field defect	2	0	2
		Horner's syndrome	1	0	1
		Hypertonia	23	0	10
		Neuroleptic malignant syndrome	11	1	3
		Serotonin syndrome	50	0	15
		Muscle contractions involuntary	1	0	0
		Myasthenia gravis	1	0	0
		Neuropathy peripheral	2	0	2
		Petit mal epilepsy	1	0	1
		Convulsion neonatal	2	0	0
		Grand mal convulsion	12	0	5
		Convulsion	58	0	32
		Convulsive threshold lowered	1	0	1
		Drug withdrawal convulsions	1	0	0
		Epilepsy	5	0	4
		Status epilepticus	2	0	2
		Tonic convulsion	1	0	1
		Circadian rhythm sleep disorder	1	0	0
		Hypersomnia	2	0	1
		Narcolepsy	1	0	0
		Poor quality sleep	2	0	2
		Nervous system disorders	938	5	621

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	5	0	4
		Intra-uterine death	1	0	1
		Foetal distress syndrome	1	1	1
		Premature labour	1	0	1
		Abnormal labour	1	0	1
		Premature separation of placenta	1	0	1
		Pre-eclampsia	2	0	2
		Pregnancy induced hypertension	1	0	1
		Ectopic pregnancy	1	0	1
		Premature baby	3	0	3
		Birth trauma	1	0	1
		Jaundice neonatal	1	0	0
		Neonatal disorder	4	0	3
		Polyhydramnios	1	0	1
		Placental disorder	1	0	1
		Unintended pregnancy	1	0	0
		Pregnancy, puerperium and perinatal conditions		26	1
	Psychiatric disorders	Agitation	80	0	60
		Agitation neonatal	2	0	2
		Anxiety	66	0	47
		Nervousness	10	0	9
		Stress	2	0	1
		Tension	1	0	1
		Fear	3	0	3
		Panic attack	9	0	7
		Panic disorder	1	0	1
		Neurosis	1	0	1
Obsessive-compulsive disorder		2	0	2	
Catatonia		1	0	0	
Decreased activity		1	0	1	
Restlessness		7	0	4	
Automatism		2	0	2	
Bruxism		10	0	9	
Posturing		1	0	1	
Stereotypy		1	0	0	
Tic		1	0	1	
Learning disorder		1	0	1	
Pressure of speech	1	0	1		
Confusional state	60	0	36		
Disorientation	15	0	10		
Delirium	19	0	12		

Medicine summary - venlafaxine (to end January 2009)

Reaction Count	Psychiatric disorders		Case Group	Death Outcomes	Sole
		Depression	35	0	26
		Depression suicidal	1	0	0
		Major depression	1	0	0
		Anhedonia	1	0	1
		Decreased interest	1	0	0
		Depressed mood	3	0	2
		Tearfulness	3	0	2
		Depersonalisation	15	0	13
		Dissociation	1	0	0
		Delusion	5	0	5
		Derealisation	1	0	0
		Hallucination	34	0	17
		Hallucination, auditory	3	0	2
		Hallucination, visual	1	0	1
		Hallucinations, mixed	1	0	1
		Thinking abnormal	18	0	13
		Eating disorder	4	0	1
		Hypomania	3	0	1
		Mania	15	0	11
		Affect lability	8	0	6
		Inappropriate affect	1	0	0
		Anger	10	0	8
		Dysphoria	2	0	1
		Elevated mood	1	0	0
		Emotional disorder	3	0	3
		Euphoric mood	5	0	4
		Mood altered	2	0	2
		Mood swings	7	0	7
		Affective disorder	1	0	0
		Apathy	6	0	6
		Aggression	39	0	27
		Disinhibition	1	0	1
		Disturbance in social behaviour	1	0	1
		Homicidal ideation	20	0	10
		Hostility	3	0	3
		Indifference	1	0	1
		Paranoia	12	0	10
		Personality change	2	0	1
		Violence-related symptom	3	0	2
		Self esteem decreased	1	0	1
		Abnormal behaviour	7	0	6
		Staring	1	0	1

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	Psychiatric disorders	Hypervigilance	1	0	0	
		Psychiatric symptom	1	0	1	
		Mental status changes	2	0	1	
		Alcohol abuse	1	0	1	
		Alcohol problem	1	0	1	
		Alcoholism	2	0	1	
		Dependence	1	0	0	
		Drug dependence	2	0	2	
		Intentional drug misuse	1	0	1	
		Withdrawal syndrome	105	0	97	
		Psychotic disorder	13	0	7	
		Schizophreniform disorder	1	0	1	
		Schizophrenia	1	0	0	
		Anorgasmia	5	0	4	
		Premature ejaculation	1	0	1	
		Libido decreased	11	0	10	
		Loss of libido	4	0	2	
		Insomnia	54	0	43	
		Abnormal dreams	10	0	8	
		Abnormal sleep-related event	5	0	0	
		Nightmare	30	0	27	
		Somnambulism	4	0	1	
		Sleep disorder	2	0	1	
		Conversion disorder	2	0	2	
		Completed suicide	12	12	9	
		Intentional self-injury	3	0	1	
		Self injurious behaviour	1	0	0	
		Self-injurious ideation	3	0	3	
		Suicidal behaviour	1	0	0	
		Suicidal ideation	82	1	56	
		Suicide attempt	56	2	38	
			Psychiatric disorders	998	15	728
		Renal and urinary disorders	Oliguria	1	0	1
			Renal failure acute	3	0	0
			Renal impairment	4	0	2
			Urethral disorder	1	0	1
Dysuria	3		0	3		
Enuresis	1		0	0		
Micturition disorder	8		0	8		
Micturition urgency	1		0	0		
Pollakiuria	4		0	4		
Urinary hesitation	2		0	2		

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Renal and urinary disorders	Urinary incontinence	9	0	7
		Urinary retention	10	0	9
		Haematuria	2	0	2
		Nocturia	1	0	1
		Polyuria	1	0	1
		Nephrolithiasis	2	0	1
		Renal and urinary disorders	53	0	42
	Reproductive system and breast disorders	Breast enlargement	1	0	0
		Gynaecomastia	7	0	5
		Breast pain	2	0	1
		Breast swelling	1	0	1
		Galactorrhoea	7	0	5
		Menstrual disorder	1	0	1
		Menstruation irregular	2	0	1
		Metrorrhagia	3	0	1
		Amenorrhoea	7	0	3
		Menorrhagia	4	0	3
		Polymenorrhoea	1	0	1
		Polycystic ovaries	2	0	1
		Penile size reduced	1	0	1
		Prostatic disorder	2	0	2
		Oedema genital	1	0	1
		Ejaculation delayed	1	0	1
		Ejaculation disorder	1	0	0
		Erectile dysfunction	4	0	2
		Priapism	1	0	1
		Sexual dysfunction	5	0	5
		Spermatorrhoea	1	0	1
		Testicular disorder	1	0	1
		Testicular pain	1	0	0
	Uterine haemorrhage	1	0	0	
	Vaginal haemorrhage	1	0	1	
	Reproductive system and breast disorders	59	0	39	
	Respiratory, thoracic and mediastinal disorders	Asthma	1	0	1
		Bronchospasm	2	0	2
		Pneumonitis	1	0	1
		Pulmonary eosinophilia	1	0	1
		Pulmonary oedema	3	1	1
		Infantile apnoeic attack	1	0	1
Pulmonary hypertension		1	0	0	
Pulmonary embolism		2	1	1	
Apnoea		3	0	2	

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Respiratory, thoracic and mediastinal disorders	Dyspnoea	19	1	12
		Hyperventilation	5	0	3
		Hypopnoea	1	0	1
		Sleep apnoea syndrome	2	0	2
		Tachypnoea	1	0	1
		Hypoxia	1	0	0
		Respiratory alkalosis	1	0	1
		Cough	3	0	2
		Hiccups	1	0	1
		Respiration abnormal	1	1	1
		Respiratory disorder	1	0	0
		Increased upper airway secretion	1	0	1
		Sneezing	1	0	1
		Throat tightness	2	0	0
		Yawning	10	0	9
		Epistaxis	3	0	2
		Oropharyngeal swelling	1	0	0
		Pharyngeal oedema	1	0	1
		Respiratory, thoracic and mediastinal disorders	70	4	48
	Skin and subcutaneous tissue disorders	Angioedema	10	0	8
		Urticaria	20	0	16
		Leukoplakia	1	0	0
		Dermatitis bullous	1	0	0
		Erythema multiforme	2	0	1
		Stevens-Johnson syndrome	1	0	0
		Cutaneous lupus erythematosus	1	0	1
		Dry skin	1	0	1
		Skin burning sensation	1	0	1
		Skin discolouration	1	0	0
Skin odour abnormal		1	0	0	
Eczema		1	0	0	
Erythema		2	0	2	
Rash erythematous		7	0	5	
Dermatitis exfoliative		1	0	0	
Skin exfoliation		3	0	3	
Rash papular		2	0	2	
Photosensitivity reaction		4	0	1	
Pruritus		39	0	28	
Pruritus generalised		1	0	0	
Rash pruritic	2	0	1		
Dermatitis psoriasiform	1	0	1		

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	Skin and subcutaneous tissue disorders	Psoriasis	1	0	0	
		Rash follicular	1	0	1	
		Rash	25	0	19	
		Rash maculo-papular	13	0	11	
		Systemic lupus erythematosus rash	1	0	1	
		Acne	3	0	3	
		Alopecia	6	0	4	
		Cold sweat	4	0	3	
		Hyperhidrosis	96	0	72	
		Hypohidrosis	1	0	1	
		Night sweats	1	0	0	
		Hirsutism	1	0	0	
		Piloerection	2	0	2	
		Ecchymosis	1	0	1	
		Purpura	16	0	14	
		Haemorrhage subcutaneous	1	0	0	
		Leukocytoclastic vasculitis	1	0	1	
		Skin and subcutaneous tissue disorders		277	0	204
		Social circumstances	Sexual abuse	1	0	1
			Activities of daily living impaired	1	0	1
Impaired work ability	1		0	1		
Social circumstances	3		0	3		
Surgical and medical procedures	Colectomy	1	0	1		
	Therapy regimen changed	16	0	11		
	Surgical and medical procedures	17	0	12		
Vascular disorders	Aneurysm	1	1	1		
	Vasospasm	1	0	1		
	Peripheral ischaemia	2	0	1		
	Poor peripheral circulation	1	0	0		
	Blood pressure fluctuation	1	0	1		
	Circulatory collapse	7	2	2		
	Hypoperfusion	1	1	1		
	Hypotension	17	1	7		
	Orthostatic hypotension	15	0	10		
	Thrombosis	1	0	1		
	Deep vein thrombosis	2	1	1		
	Thrombophlebitis	1	0	0		
	Vasodilatation	1	0	1		
	Flushing	20	0	15		
	Hot flush	5	0	4		
	Pallor	4	0	2		
	Haemorrhage	1	0	1		

Medicine summary - venlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Vascular disorders	Hypertension	47	0	32
		Maternal hypertension affecting foetus	1	0	0
		Vasculitis	1	0	1
	Vascular disorders		130	6	82
Reaction			4270	73	2992